Brief: Mainz Biomed Acquires Exclusive Rights To Novel mRNA Biomarkers For Integration Into ColoAlert
05/01/2022 08:13
Jan 5 (Reuters) - Mainz Biomed BV 4TO.F :
* MAINZ BIOMED ACQUIRES EXCLUSIVE RIGHTS TO NOVEL MRNA
BIOMARKERS
* MAINZ BIOMED BV - ENTERED INTO A AGREEMENT WITH SOCPRA
SCIENCES
SANTÉ ET HUMAINES S.E.C. TO ACCESS A PORTFOLIO OF NOVEL MRNA
BIOMARKERS
* MAINZ BIOMED -HAS UNILATERAL OPTION TO LICENSE GLOBAL
RIGHTS TO
5 GENE EXPRESSION BIOMARKERS HAVING DEMONSTRATED EFFECTIVENESS
IN DETECTING CRC LESIONS INCLUDING "AA"
Source text for Eikon: ID:nGNX5Qr40Q
Further company coverage: 4TO.F
((reuters.briefs@thomsonreuters.com;))
Recent news on Quantum Cyber NV
See all newsBrief: Quantum Cyber To Proceed With Pending Litigation Against Adam Gefvert
Brief: Quantum Cyber NV Files Lawsuit Against White Diamond Research, Adam Gefvert And Stocktwits, Inc. In New York Supreme Court
Quantum Cyber jumps on SpaceX stake purchase plan
Brief: Quantum Cyber Signs Loi To Acquire An Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility To Support Mass-Scale Autonomous Drone Production
Brief: Quantum Cyber NV - To Terminate ATM Sales Agreement With Maxim Effective June 7, 2026 - SEC Filing